GovWire

Chronic hand eczema is an inflammatory skin condition that causes symptoms such as itching and pain.

Anzupgo contains the active substance delgocitinib, which belongs to a group of medicines called Janus kinase inhibitors.

Delgocitinib works by blocking the activity of four specific Janus kinase enzymes, which helps reduce inflammation and immune responses that cause hand eczema. By suppressing these processes, delgocitinib can help to reduce inflammation of the skin, itching and pain. This, in turn, can increase the ability to perform daily activities and can improve the quality of life.

As with any medicine, the MHRA will keep the safety and effectiveness of delgocitinib under close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.

ENDS

Notes to editors

1. The new marketing authorisation was granted in 59 days on 29 November 2024 to Leo Pharma AS under the International Recognition Procedure (IRP) Route B.
2. The Reference Regulator (RR) was the European Medicines Agency (EMA), with the procedure number (EMEA/H/C/006109/0000).
3. More information can be found in the Summary of Product Characteristics and Patient Information leaflets which will be published on theMHRA Products websitewithin 7 days of approval.
4. The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe. All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.
5. The MHRA is an executive agency of the Department of Health and Social Care.
6. For media enquiries, please contact thenewscentre@mhra.gov.uk, or cal
   

   View the original news story